Objective. Rheumatoid arthritis (RA) patients have an increased risk of developing cardiovascular diseases (CVD). Other autoimmune diseases such as hypothyroidism are also associated with an enhanced risk for CVD. Our objective was to determine first, the prevalence of hypothyroid disorders in RA patients, and second, the risk of CVD in RA patients with hypothyroid abnormalities.
INTRODUCTION
Several investigators have reported similarities between atherosclerosis and inflammatory autoimmune diseases such as rheumatoid arthritis (RA). (1) (2) (3) There is increasing evidence for the important role of inflammation in the development and progression of atherosclerosis. Inflammation may change a stable plaque into an unstable plaque and can cause thrombosis, which will frequently precipitate acute vascular events. Furthermore, it has been demonstrated that RA is associated with an excess of cardiovascular mortality.(4) Moreover there is a high prevalence of preclinical carotid atherosclerosis in patients with rheumatoid arthritis.(5) Hence, generalised autoimmune diseases can be an additional risk factor for the development of CVD. (4) Hypothyroidism can cause dyslipidemia characterized by an elevated LDL cholesterol (LDLc) and a total cholesterol (TC) by the induction of a decreased uptake of LDLc by liver cells.(6) Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women and it is associated with an insulin resistance related dyslipidemia in RA patients. (7) (8) Therefore, clinical and subclinical hypothyroidism are generally considered to be risk factors for CVD.
However, in a very recent, population-based investigation, subclinical hypothyroidism was found not to be associated with incident cardiovascular diseases. (9) There are scarce data available about the prevalence of CVD in patients with thyroid disorders. In the first systematic controlled autopsy study a higher prevalence of myocardial infarction in myxedema patients was found in comparison with euthyroid controls. (10) Another autopsy study demonstrated a higher incidence of severe coronary artery diseases in hypothyroid patients independent of hypertension, diabetes mellitus, or obesity.(11) Both autopsy studies have methodological limitations and conclusions of these autopsy studies are therefore difficult to interpret.(12)
The present study was undertaken to investigate the question whether hypothyroidism occurs more frequently in RA patients and to investigate the association of hypothyroidism with prevalent CVD in RA.
PATIENTS AND METHODS

Study population
For this study three hundred fifty eight RA patients, participating in an ongoing prospective cohort study of cardiovascular mortality and morbidity in RA patients performed in the Jan van Breemen Institute (JBI), Amsterdam, were included. All RA patients registered at the JBI were eligible for participation; the study-population was randomly selected and subsequently recruited during regular outpatient visits. The participants were enrolled between January 2001 and January 2002. The patients' ages ranged from 50 to 75 and RA was diagnosed according to the 1987 ACR criteria.(13) At the inclusion visit patients' demographic, clinical and laboratory data (including the assessment of thyroid function) were collected. The data and blood sera were obtained by systematic chart reviews of the medical notes.
Thyroid abnormalities
This study focused on hypothyroidism, hence we excluded hyperthyroid patients, resulting in three subgroups: i.e. subclinical hypothyroidism, clinical hypothyroidism and euthyroidism. Clinical hypothyroidism was defined by a documented medical history of hypothyroidism or by the criteria for thyroid abnormalities as defined by the Dutch national healthcare consensus committee.
Subclinical hypothyroidism was defined by a an increased (> 4.0 mU/l) serum thyroid stimulating hormone (TSH) in the presence of a normal (11-25 pmol/l) serum free thyroxine (fT4) assessed from blood samples.
As reference for thyroid abnormalities the age adjusted prevalence in the general population data of the Dutch national healthcare consensus committee was used.(14-15)
RA related data
The 28 joints' disease activity score (DAS 28) was assessed to measure the disease activity. 
Laboratory tests
TSH and fT4 were assessed in all patients by the Elecsys test. IgM rheumatoid factor (IgM-RF) and anti cyclic citrullinated peptides (anti-CCP) antibodies were measured using in-house enzyme linked immunosorbent assays on an ES 300 analyser (Roche Diagnostics).
Statistical analyses
The prevalence of the hypothyroid subgroups was compared with the general population by means of a binomial test. The population-based prevalence was adjusted for age and gender. All patients suffering from (sub)clinical hypothyroidism were compared with the euthyroid patients for RA and CVD related parameters. The RA and CVD related data of the subgroups of thyroid dysfunction were compared, using Pearson's Chi square test for dichotomous variables and using Mann-Whitney test for continuous variables. Logistic regression analysis was used to calculate the odds ratio (OR) with 95% confidence interval (CI) for thyroid disorders as risk factors for CVD. This OR was adjusted for possible confounders: i.e. age, gender, diabetes, smoking, hypertension, statin use, renal insufficiency, rheumatoid factor and disease duration. A P-value below 0.05 was considered to be statistically significant. For all analyses SPSS 13.0 for Windows (SPSS, Inc., Chicago, Illinois) was used.
RESULTS
Patients
The main characteristics of our population are shown in table 1. In this study 358 patients with RA were evaluated, 236 of which were women (66%). All patients with clinical hypothyroidism (n=16) were women, which is significantly higher than in the other subgroups (subclinical hypothyroidism and euthyroidism), of which respectively 6/10 and 194/308 (approximately 60% in all the other subgroups) were women (p=0.001). The median age in euthyroid women (62) was significantly lower (P = 0.02) than that in hypothyroid women (68). Cardiovascular risk factors did not differ (significantly) between (sub)clinical hypothyroid and euthyroid RA patients. 
Thyroid abnormalities
In the RA population under study clinical hypothyroidism was more frequently present in women than in men; 6.8% (95%-CI: 5.1-8.4) of the women had clinically manifest hypothyroidism in comparison with the 2.7% observed in the Dutch population (P < 0.001) (table 2). In female RA patients subclinical hypothyroidism was less prevalent than in the general female population, 2.5%
(95%-CI: 1.5-3.6) versus 18%, respectively (P < 0.001). Table 3 shows that RA patients with clinically manifest hypothyroidism had significantly more CVD in comparison with euthyroid RA patients, 37.5% and 13.0% (p = 0.05), respectively (OR 3.1 95%-CI: 1.1-8.9). After adjustments for the possible confounders age and gender the OR for CVD in hypothyroid RA patients was 3.2 (95%-CI: 1.0-10.1). After adjustments for the possible confounders age, gender, diabetes, smoking, hypertension, statin use and renal insufficiency, the OR was 4.6 (95%-CI: 1.3-
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16.7).
The possible confounders rheumatoid factor and disease duration had no influence on any of the models. 
DISCUSSION
The main conclusion of the present study is an almost threefold enhanced prevalence of clinical hypothyroidism in secondary care female RA patients in comparison with the general population. In female RA patients, clinical hypothyroidism was associated with a fourfold higher risk of CVD in comparison with euthyroid female RA patients independently of the traditional risk factors. No clinically manifest hypothyroidism was found in men, which is in accordance with previous observations which proved that thyroid abnormalities are sex related, albeit that the number of studied males was relatively small in our investigation. (18) The present study shows a prevalence of subclinical hypothyroidism in female RA patients which is lower than in a sex and age matched general population. This finding might be explained by the pyramid hypothesis. This hypothesis is based on the observation that subclinical hypothyroidism will develop into clinically manifest hypothyroidism in approximately one quarter of the cases. Hence, our finding of the threefold enhanced prevalence of hypothyroidism in female RA patients, who are at increased risk of CVD (particularly, ischemic heart disease and congestive heart failure which both are not fully explained by traditional Framingham risk factors),(32) is important, as in hypothyroid patients endothelium dysfunction is found which is related to dyslipidaemia as well as systemic inflammation, which might accelerate the development of CVD in the already high risk RA patients.
The cross sectional design of this study can be perceived as a limitation because it is difficult to establish the direction of the observed association. However, as most patients first developed hypothyroidism before clinically apparent cardiovascular disease, it appears that hypothyroidism contributes to the amplification of the cardiovascular risk in RA . 
